Keyuan Pharmaceutical released an earnings forecast, expecting net profit attributable to the parent for the first half of 2026 to be between 60 million yuan and 65 million yuan, an increase of 40.57% to 52.29% from 42.68 million yuan in the same period last year. Net profit after deducting non-recurring items is expected to be between 52 million yuan and 57 million yuan, compared with 35.87 million yuan a year earlier, representing growth of 44.97% to 58.91%. The profit growth is mainly due to intensified efforts in developing the formulation market, the introduction of new products boosting sales, and optimized operational management improving production efficiency, which lifted gross margins for formulation products. In addition, after settling a contract dispute between a wholly owned subsidiary and Jiangsu Saibang Pharmaceutical Co., Ltd., the company paid 8 million yuan. Keyuan Pharmaceutical had already accrued 16.107 million yuan in non-operating expenses for 2025, and reversed 8.107 million yuan in the current period, which had a positive impact on profit. In the first quarter of 2026, Keyuan Pharmaceutical achieved revenue of 161 million yuan and net profit attributable to the parent of 30.07 million yuan.
Shandong Keyuan Pharmaceutical Co. Ltd. ACompany expects 40.57%-52.29% net profit growth for H1 2026 due to market development, new products, and operational improvements.
Mentioned as counterparty in a contract dispute settled by Keyuan Pharmaceutical, paying 8 million yuan.